By Fineline Cube 
Innovent Biologics (HKG: 1801) announced that its Suzhou commercialization base successfully passed the on‑site Good Manufacturing Practice (GMP) inspection by the European Medicines Agency (EMA) on its first attempt and officially received EU GMP certification. The milestone validates the company’s high‑end biopharmaceutical manufacturing platform against one of the world’s most stringent regulatory standards.
Regulatory Milestone
| Field | Detail |
|---|---|
| Agency | European Medicines Agency (EMA) |
| Inspection Type | On‑site GMP inspection — passed on first attempt |
| Certification | EU GMP certification officially received |
| Site | Suzhou commercialization base, Innovent Biologics (HKG: 1801) |
| Compliance Standards | Built to NMPA, FDA, and EMA GMP standards |
| Date | 07 Sep 2026 |
| Next Steps | Supports global supply and commercialization of biologics from the Suzhou base |
Manufacturing Base Profile
| Facility | Building Area | Production Capacity | Key Features |
|---|---|---|---|
| Site 1 | 93,000 square meters | 60,000 liters (antibody) | Includes an ADC manufacturing line |
| Site 2 | 176,000 square meters | 80,000 liters (antibody) | Large‑scale antibody production |
| Total | — | 140,000 liters operational capacity | ~20% of China’s total biomanufacturing capacity |
The Suzhou base has been constructed in compliance with NMPA, FDA, and EMA GMP standards, positioning it as a globally aligned commercialization platform. Site 1 pairs 60,000 liters of antibody production capacity with a dedicated ADC (antibody‑drug conjugate) manufacturing line, while Site 2 adds 80,000 liters of antibody capacity across 176,000 square meters of building area.
Market Impact & Outlook
- Global Standard Validation: Passing the EMA on‑site GMP inspection on the first attempt — and receiving official EU GMP certification — demonstrates manufacturing quality aligned with European regulatory expectations.
- Scale Leadership: With 140,000 liters of operational capacity, representing 20% of China’s total capacity, Innovent Biologics has achieved the world’s largest single‑batch antibody production scale.
- Tri‑Standard Compliance: The base’s alignment with NMPA, FDA, and EMA GMP requirements supports multi‑regional regulatory filings and supply continuity.
- Modality Breadth: Combined antibody and ADC manufacturing capability positions the Suzhou site to serve both the company’s current biologics portfolio and next‑generation conjugate programs.
- Commercialization Readiness: EU GMP certification strengthens the base’s role as a high‑end biopharmaceutical commercialization hub for international markets.
Forward‑Looking Statements — This brief contains forward‑looking statements regarding Innovent Biologics‘ Suzhou commercialization base, its EU GMP certification following the EMA on‑site inspection, and the future global supply and commercialization of its antibody and ADC products. Such statements are based on current expectations and are subject to risks and uncertainties, including regulatory, manufacturing, and commercialization risks. Actual results may differ materially. Nothing herein constitutes investment advice or an offer to buy or sell any securities.-Fineline Info & Tech